

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

OTHER RELEVANT INFORMATION

Following the "Other Relevant Information" note communicated on 7 September 2020, Grifols informs that it has closed the transaction by means of which Grifols acquires the remaining shares of Alkahest, Inc. ("**Alkahest**") (approximately 55%) in exchange of a total price of \$146 million, on a debt free basis. \$20 million have been paid at closing of the transaction and the remaining amount will be paid on 1 February 2021. With this transaction, Grifols gains total control of Alkahest.

Alkahest is a clinical stage biopharmaceutical company targeting neurodegenerative and age-related diseases with transformative therapies derived from a deep understanding of the plasma proteome in aging and disease.

In Barcelona, on 15 December 2020

Nuria Martín Barnés
Secretary to the Board of Directors